HUTCHMED (China) Limited announced that its partner AstraZeneca has secured regulatory review for the ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) regimen in both Europe and Japan, targeting patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) exhibiting MET overexpression or amplification and disease progression on prior EGFR tyrosine kinase inhibitor (TKI) therapy.
The European Medicines Agency has validated the Marketing Authorization Application, while Japan’s Ministry of Health, Labour and Welfare has accepted a New Drug Application. These submissions follow a U.S. FDA New Drug Application filed in September 2026, underscoring coordinated global expansion efforts for the combination therapy.
Regulatory dossiers are anchored by the global Phase III SAFFRON trial, which enrolled 338 patients across 29 countries. Key outcomes include:
• Progression-free survival (primary endpoint): Hazard ratio 0.55 (95% CI 0.42-0.72; p<0.001), representing a 45% reduction in the risk of disease progression or death versus doublet platinum-based chemotherapy. Median PFS reached 7.6 months for the combination versus 5.4 months for chemotherapy.
• Overall survival (key secondary endpoint): Hazard ratio 0.68 (95% CI 0.50-0.91; p=0.010), equating to a 32% reduction in mortality risk. Median OS extended to 17.8 months compared with 12.9 months for the control arm.
The safety profile aligned with established data for both agents, and no new concerns emerged.
Third-generation EGFR-TKIs have reshaped EGFR-mutated NSCLC management; however, MET overexpression or amplification remains a prevalent resistance pathway, affecting approximately one-third of patients after progression on TAGRISSO. The ORPATHYS–TAGRISSO regimen addresses this high-unmet-need segment.
ORPATHYS is already approved in China for MET exon 14 skipping NSCLC and conditionally approved for metastatic gastric or gastroesophageal junction adenocarcinoma with MET amplification. In China, the ORPATHYS–TAGRISSO combination is authorized for EGFR-mutated, MET-amplified NSCLC post-EGFR-TKI therapy, and holds temporary authorization in Switzerland. Acceptance of filings in Europe and Japan, alongside the ongoing U.S. review, positions the partnership to potentially broaden the therapy’s global footprint.
The SAFFRON data were highlighted at the 2026 European Society for Medical Oncology Presidential Symposium and published in The New England Journal of Medicine, reinforcing the clinical significance of the observed efficacy gains in both PFS and OS.
No financial details regarding potential revenues or timelines for approval were disclosed in the announcement.
Comments